Home Journals Articles Updates About
CN
image
收藏切换
Evidence-based analysis of the current status of clinical trials for obesity and overweight drugs in China and abroad
收藏切换
PDF
Fei LIU1, Qi-qiong DING2, Hui-qing YAO3, Xi-qian XIE3, Hai-juan Zhao3, Juan WANG3, Yue-xiong ZHANG4, Lei CAI5, Zhen-yu ZHAO1
Chinese Journal of Clinical Pharmacology | 2026, 42(7) : 1041 - 1045
Less
收藏切换
Chinese Journal of Clinical Pharmacology | 2026, 42(7): 1041-1045
• Special Column of Clinical Trials Administration •
Evidence-based analysis of the current status of clinical trials for obesity and overweight drugs in China and abroad
Full
Fei LIU1, Qi-qiong DING2, Hui-qing YAO3, Xi-qian XIE3, Hai-juan Zhao3, Juan WANG3, Yue-xiong ZHANG4, Lei CAI5, Zhen-yu ZHAO1
Affiliations
  • 1.NHC Key Lab of Hormones and Development and Tianjin Key Lab of Metabolic Diseases, Tianjin Medical University Chu Hsien-I Memorial Hospital & Institute of Endocrinology, Tianjin 300134, China
  • 2.Clinical Pharmacology Research Center, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China
  • 3.Clinical Trial Center, Beijing Hospital, National Center for Gerontology; National Clinical Research Center for Gerontology; The Key Laboratory of Geriatrics of NHC; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, P.R. China
  • 4.Tianjin Jizhou District People′s Hospital, Tianjin 301900, China
  • 5.Central Hospital, Tianjin University /Tianjin Third Central Hospital, Tianjin 300170, China
Published: 2026-04-17 doi: 10.13699/j.cnki.1001-6821.2026.07.023
Outline
收藏切换
Objective

To analyze the strengths and weaknesses of China’s R&D in obesity/overweight drug clinical trials by comparing domestic and international trial characteristics, and put forward suggestions based on national conditions.

Methods

Clinical trial data of drugs for overweight/obesity were retrieved from ClinicalTrials.gov (CT.gov) and the China Drug Clinical Trial Registration and Information Disclosure Platform (Registration Platform), and divided into a domestic trial group and an international trial group. A bibliometric method was used for comparative analysis from the dimensions of drug type, dosage form, trial design, number of trials, age, gender, and sample size.

Results

Domestically, chemical drugs dominated (77.57%, 211 cases/271 cases), while international trail chemical drugs (51.30%, 256 cases/499 cases) and biological products (48.30%, 241 cases/499 cases) developed balancedly. Domestic trials focused on tablets (46.32%, 126 cases/271 cases) and injections (47.06%, 128 cases/271 cases), whereas international trials were dominated by injections (57.52%, 287 cases/499 cases) (P<0.001). Domestic randomization rate (92.25%, 250 cases/271 cases) was much higher than overseas (79.56%, 397 cases/499 cases), but blinding application was lower (44.65%, 121 cases/271 cases vs. 65.33%, 326 cases/499 cases). Few domestic trials included children (1.11%, 3 cases/271 cases), with only 3 female-specific studies.

Conclusion

Global obesity/overweight drug trials are mainly in China and the US, but China lags behind with unbalanced structure and insufficient population representativeness. China should improve R&D level through policy incentives and international cooperation based on clinical needs.

overweight  /  obesity  /  weight loss  /  pharmaceutical clinical trials  /  clinical trial registration
Fei LIU, Qi-qiong DING, Hui-qing YAO, Xi-qian XIE, Hai-juan Zhao, Juan WANG, Yue-xiong ZHANG, Lei CAI, Zhen-yu ZHAO. Evidence-based analysis of the current status of clinical trials for obesity and overweight drugs in China and abroad[J]. Chinese Journal of Clinical Pharmacology, 2026 , 42 (7) : 1041 -1045 . DOI: 10.13699/j.cnki.1001-6821.2026.07.023
Appendix
Less
Year 2026 volume 42 Issue 7
PDF
126
25
Cite this Article
BibTeX
Article Info
doi: 10.13699/j.cnki.1001-6821.2026.07.023
  • Receive Date：2025-12-17
  • Online Date：2026-08-06
  • Published：2026-04-17
Article Data
Affiliations
History
  • Received：2025-12-17
Funding
Affiliations
    1.NHC Key Lab of Hormones and Development and Tianjin Key Lab of Metabolic Diseases, Tianjin Medical University Chu Hsien-I Memorial Hospital & Institute of Endocrinology, Tianjin 300134, China
    2.Clinical Pharmacology Research Center, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China
    3.Clinical Trial Center, Beijing Hospital, National Center for Gerontology; National Clinical Research Center for Gerontology; The Key Laboratory of Geriatrics of NHC; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, P.R. China
    4.Tianjin Jizhou District People′s Hospital, Tianjin 301900, China
    5.Central Hospital, Tianjin University /Tianjin Third Central Hospital, Tianjin 300170, China
References
Share
https://castjournals.cast.org.cn/joweb/zglcylxzz/EN/10.13699/j.cnki.1001-6821.2026.07.023
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family		 属数
Number of
genus		 种数
Number of
species		 占总种数比例
Percentage of
total species (%)		 属
Genus		 种数
Number of
species		 占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT
Links
Articles
Latest Articles
Most Read
Collections
Updates
Events
News
Multimedia
About
About Us
Contact
No. 86 Xueyuan South Road, Haidian District, Beijing
100081
010-62199257
qkjq@cast.org.cn

Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House